Clinical trials: Iron Overload
Iron Overload
Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia
The study is designed to collect safety and efficacy of Desferasirox in Chinese patients with Iron Overload and Aplastic Anemia.
- Trial name
- NCT01546415
- Testing
- Desferasirox
- Where
- 7 sites in China
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Neurodegenerative Diseases, Parkinson Disease
Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal…
- Conditions
- Neurodegenerative Diseases, Parkinson Disease, Synucleinopathies, Lewy Body Disease
- Trial name
- MARKERS-NDD (NCT06596746)
- Testing
- Observation
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Casa di Cura San Raffaele Cassino
Hemochromatosis
Erythrocyte Apheresis Versus Phlebotomy in Hemochromatosis
Primary hemochromatosis is the most frequent hereditary condition in Scandinavia. The condition may result in serious organ damage which can be prevented by therapy, but only few patients develop such organ damage.
- Trial name
- NCT00509652
- Testing
- Arm 1: Erythrocyte apheresis, Arm 2: Whole blood phlebotomy
- Where
- 3 sites in Norway
- Volunteers
- 67 people
- Sponsor
- University of Bergen
Genetic Hemochromatosis
Bone Status on Patients With Genetic Hemochromatosis: a 3 Years Descriptive and Evolutionary Study
The purpose of this study is to describe bone status on patients with genetic hemochromatosis, at diagnostic time and his evolution under treatment.
- Trial name
- FEROS (NCT01556360)
- Where
- 6 sites in France
- Volunteers
- 100 people
- Sponsor
- Rennes University Hospital
Sickle Cell Disease, Iron Overload
Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients
This study will examine the long-term safety and efficacy of Deferasirox in patients with sickle cell disease and iron overload from repeated blood transfusions.
- Conditions
- Sickle Cell Disease, Iron Overload, Hemolytic Anemia
- Trial name
- NCT00110617
- Testing
- Deferasirox (ICL670), Deferoxamine (DFO)
- Where
- 59 sites in United States, Canada
- Volunteers
- 212 people
- Sponsor
- Novartis Pharmaceuticals
Hemochromatosis, Cerebrovascular Accident
Stroke With Transfusions Changing to Hydroxyurea
The purpose of this study is to compare standard therapy (transfusions and chelation) with alternative therapy (hydroxyurea and phlebotomy) for the prevention of secondary stroke and management of iron overload in children with…
- Conditions
- Hemochromatosis, Cerebrovascular Accident, Anemia, Sickle Cell, Hematologic Diseases
- Trial name
- NCT00122980
- Testing
- Red Cell Transfusions, Iron Chelation, Hydroxyurea
- Where
- 28 sites in United States
- Volunteers
- 134 people
- Sponsor
- St. Jude Children's Research Hospital
Iron Overload, Cardiomyopathy
Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major
Myocardial iron overload is the leading cause of death in patients with beta-thalassemia major (TM). Therapy with deferoxamine (DFO) combined with deferiprone (DFP) reduces myocardial iron and improves cardiac function.
- Trial name
- DFODFPTM (NCT00800761)
- Testing
- Deferoxamine and Deferiprone, Deferoxamine
- Where
- Italy
- Sponsor
- Ospedale Microcitemico
Hemolytic Anemia, Thalassemia
Native T1 Mapping and ECV in Chronic Hemolytic Anemia
This cross-sectional study aims to evaluate the diagnostic performance of native T1 mapping and extracellular volume fraction for the detection of myocardial iron overload and fibrosis in patients with chronic hemolytic anemia…
- Conditions
- Hemolytic Anemia, Thalassemia, Iron Overload
- Trial name
- NCT07882303
- Volunteers
- 54 people
- Sponsor
- Assiut University
Myelodysplastic Syndromes, Hemosiderosis
Safety, Tolerability, and Efficacy of Deferasirox in MDS
Open label, single arm study on Deferasirox treatment in MDS patients with chronic transfusional hemosiderosis. Patients receive daily oral dosis of Deferasirox in order to eliminate the quantity of iron administered during…
- Trial name
- NCT00469560
- Testing
- Deferasirox
- Where
- 17 sites in Italy
- Volunteers
- 158 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Hemosiderosis
Pharmacogenetic Study in Patients Received Iron Chelating Agent
To investigate effect of genetic variations on the toxicities and find optimal target population, the investigators planned to analyze the genetic polymorphisms of UDP-glucuronosyltransferase.
- Trial name
- NCT01623895
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Seoul National University Hospital
Hemochromatosis
Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis
Hereditary Hemochromatosis (HH) is a genetic disorder of iron metabolism, resulting in excessive iron overload causing damage of different important organs like heart, liver, pancreas and joints.
- Trial name
- He-ppi (NCT01524757)
- Testing
- Pantoprazole
- Where
- 3 sites in Belgium, Netherlands
- Volunteers
- 48 people
- Sponsor
- Maastricht University Medical Center
Iron Overload
Safety and Efficacy of Iron Reduction by Phlebotomy
Hypothesis: The reduction of total body iron by phlebotomy will be safe and feasible in the post-HSCT setting Iron overload is common after hematopoietic stem cell transplantation.
- Trial name
- NCT00689182
- Testing
- monthly phlebotomy x 12 months
- Where
- Canada
- Volunteers
- 23 people
- Sponsor
- Andrea Kew
Sickle Cell Disease, Thalassemia
Genes Influencing Iron Overload State
Iron overload, which can be defined operationally as too much iron in the body, develops as a consequence of too many blood transfusions given, or due to genetic defects hereditary hemochromatosis).
- Conditions
- Sickle Cell Disease, Thalassemia, Marrow Aplasia
- Trial name
- NCT01158794
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- St. Jude Children's Research Hospital
Platelet Changes in Cases of Iron Overload
Platelet Changes in Cases of Chronic Iron Over Load
Iron demand: The average daily demand to fit the cell biological metabolism is balanced between intake and lost which about 1-2 mg.
- Trial name
- NCT04329286
- Volunteers
- 50 people
- Sponsor
- Assiut University
Healthy Volunteers, Overweight
Evaluation of Body Iron Stores in Overweight Healthy Volunteers
Normal body iron store value in overweight subjects is currently not described in literature. The comparison of this value with body iron levels in patients suffering from dysmetabolic iron overload syndrome (DIOS) could allow to…
- Trial name
- FERNORM (NCT02304874)
- Testing
- Phlebotomy
- Where
- France
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Rennes University Hospital
Hemochromatosis
Treatment of Hemochromatosis
This study will evaluate the effectiveness of a test called MCV in guiding phlebotomy (blood drawing) therapy in patients with hemochromatosis an inherited disorder that causes too much iron to be absorbed by the intestine.
- Trial name
- NCT00007150
- Testing
- Phlebotomy
- Where
- United States
- Volunteers
- 622 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Transfusion-dependent β-thalassemia Patients, Cardiac Iron Overload
Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload
The primary efficacy endpoint of this interventional study was to evaluate the number of patients achieving a complete response (CR), defined as patients switching from intensive deferasirox -DFO treatment, at any time point…
- Trial name
- NCT01459718
- Testing
- Deferasirox, Deferoxamine (DFO)
- Where
- 4 sites in Greece
- Volunteers
- 32 people
- Sponsor
- Novartis Pharmaceuticals
Transfusional Iron Overload, Transfusional Hemosiderosis
Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload
This is a clinical research study in patients who have iron overload in the heart due to chronic blood transfusions. The study will have 2 treatment groups and will compare the safety and efficacy of chelation therapy with a…
- Trial name
- CORDELIA (NCT00600938)
- Testing
- Core Study: Deferasirox, Core Study: Deferoxamine, Extension: deferoxamine to deferasirox
- Where
- 21 sites in Canada, China and 9 more
- Volunteers
- 197 people
- Sponsor
- Novartis Pharmaceuticals
Neurodegenerative Disease, Iron Overload
Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)
This trial is a multicenter, unblinded, single-arm pilot study, lasting one year (plus one year extension Amendment n.3 25 August 2009, plus two years follow-up Amendment n.7) , to evaluate the efficacy and safety of the chelator…
- Trial name
- NCT00907283
- Testing
- Deferiprone
- Where
- 3 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Ente Ospedaliero Ospedali Galliera
Transfusional Iron Overload, Iron Overload
Treatment of Iron Overload Requiring Chelation Therapy
The purpose of this open-label study is to assess liver iron concentration using MRI imaging in subjects with beta-thalassemia when administered with either SPD602 or deferasirox for the treatment of chronic transfusional iron…
- Conditions
- Transfusional Iron Overload, Iron Overload, Iron Chelation, Beta-thalassemia
- Trial name
- NCT01927913
- Testing
- SPD602, Deferasirox
- Sponsor
- Shire